What is the target dose of Wellbutrin (bupropion hydrochloride) for an adult patient, aged 18 years or older, with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition, seeking weight management?

Bupropion for Weight Management: Target Dosing

For weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, bupropion is prescribed as naltrexone-bupropion ER combination therapy with a target maintenance dose of 32 mg naltrexone/360 mg bupropion daily (two tablets twice daily), not as bupropion monotherapy. 1, 2

Critical Context: Bupropion Monotherapy is NOT FDA-Approved for Weight Management

• Bupropion alone is not FDA-approved for weight management 2, 3
• The FDA-approved formulation for chronic weight management is the combination product naltrexone-bupropion ER (Contrave), which contains 8 mg naltrexone and 90 mg bupropion per tablet 1, 2
• The combination works through dual mechanisms: bupropion activates anorexigenic neurons in the hypothalamus while naltrexone blocks β-endorphin-mediated auto-inhibition of these neurons, potentiating the weight loss effect 2, 4

Recommended Titration Schedule for Naltrexone-Bupropion ER

Week 1: 1 tablet once daily in the morning (8 mg naltrexone/90 mg bupropion) 1, 2, 4

Week 2: 1 tablet twice daily (morning and evening) 1, 2, 4

Week 3: 2 tablets in the morning, 1 tablet in the evening 1, 2, 4

Week 4 and beyond: 2 tablets twice daily (maintenance dose = 32 mg naltrexone/360 mg bupropion daily) 1, 2, 4

Important Timing Consideration

• The second dose should not be taken late in the day to minimize insomnia risk 2, 5

Efficacy Assessment and Discontinuation Criteria

At 12 weeks on maintenance dose: If the patient has not lost at least 5% of baseline body weight, the medication should be discontinued as they are likely a poor responder 1, 2

• Expected weight loss: 10.3-12.4% total body weight loss over 68 weeks compared to placebo in clinical trials 1
• More patients achieve ≥5% weight loss with naltrexone-bupropion ER (40% vs 16% placebo in intent-to-treat analysis) 6

Dose Adjustments for Special Populations

Moderate to severe renal impairment: Reduce total daily dose by one-half (1 tablet twice daily instead of 2 tablets twice daily) 2, 5

End-stage renal disease: Avoid use 2, 5

Moderate to severe hepatic impairment: Maximum dose should not exceed 1 tablet daily 2, 5

Mild hepatic impairment: Consider dose reduction and/or frequency adjustment 5

Critical Safety Monitoring

Blood pressure and heart rate: Monitor periodically, especially during the first 12 weeks, as naltrexone-bupropion ER can cause elevations in both parameters 2, 3, 4

Neuropsychiatric effects: Monitor for suicidal ideation and behavior, particularly in patients younger than 24 years 2, 5

Seizure risk: The maximum bupropion dose in this combination (360 mg daily) maintains seizure risk at approximately 0.1%, but avoid in patients with seizure disorders or conditions that lower seizure threshold 2, 3

Absolute Contraindications

• Uncontrolled hypertension 2, 3, 4
• Seizure disorders or conditions predisposing to seizures 2, 3, 4
• Current opioid use (naltrexone will precipitate severe withdrawal) 2, 5, 4
• Use of MAOIs within 14 days 2, 3
• Pregnancy and breastfeeding 1, 3
• Eating disorders (bulimia or anorexia nervosa) 2, 3
• Abrupt discontinuation of alcohol, benzodiazepines, or antiepileptic drugs 5

Common Pitfalls to Avoid

• Do not prescribe bupropion monotherapy for weight management - it lacks FDA approval for this indication and the evidence supports only the combination product 2, 3
• Do not skip the gradual titration schedule - rapid dose escalation increases adverse effects, particularly nausea and seizure risk 1, 2
• Do not continue beyond 12 weeks without adequate response - patients who haven't lost 5% body weight by week 12 are unlikely to benefit from continued therapy 1, 2
• Do not use in patients on chronic opioid therapy - this is an absolute contraindication due to the naltrexone component 2, 5, 4